Alcoholic liver disease - Established treatment and new therapeutic approaches;Alkoholische lebererkrankung - Etablierte und experimentelle therapieansätze

Zeitschrift fur Gastroenterologie

Volumn 41, Issue 4, 2003, Pages 333-342

  Stickel, Felix ^a   Seitz, H K ^b   Hahn, E G ^a   Schuppan, D ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b Krankenhaus Salem   (Germany)

Author keywords

Alcoholic liver disease; Anti TNF ; Colchicine; Cytochrome P450 2E1; Liver cirrhosis; Liver transplantation; Metadoxin; Nutritional therapy; Pentoxifylline; Polyenylphosphatidylcholine; S adenosyl 1 methionine; Silymarin

Indexed keywords

ACETALDEHYDE; ANABOLIC AGENT; CORTICOSTEROID; CYTOCHROME P450 2E1; CYTOCHROME P450 INHIBITOR; METADOXINE; PENTOXIFYLLINE; PHOSPHATIDYLCHOLINE; POLYENE PHOSPHATIDYLCHOLINE; S ADENOSYLMETHIONINE; SILYMARIN; TRACE ELEMENT; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

ABSTINENCE; ALCOHOL LIVER CIRRHOSIS; ALCOHOL LIVER DISEASE; DIET THERAPY; DISEASE SEVERITY; DRUG EFFICACY; HUMAN; LIVER INJURY; LIVER TRANSPLANTATION; MACRONUTRIENT; NUTRITIONAL STATUS; PSYCHOTHERAPY; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; TREATMENT INDICATION;

CLINICAL TRIALS; COMBINED MODALITY THERAPY; DRUGS, INVESTIGATIONAL; HUMANS; LIVER DISEASES, ALCOHOLIC; LIVER FUNCTION TESTS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0038222593     PISSN: 00442771     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-38646     Document Type: Review

References (93)

1. Salaspuro M. Epidemiological aspects of alcoholic liver disease, ethanol metabolism, and pathogenesis of alcoholic liver disease. In: Bircher J, Benhamou JP, McIntyre N et al. (Hrsg). Oxford Textbook of Clinical Hepatology. Oxford: University Press 1999; 1157-1184
2. Lieber CS. Alcohol and the liver: 1994 update. Gastroenterology 1994; 106: 1085-1105
3. Jokelainen K, Reinke LA, Nanji AA. Nf-kappa B activation is associated with free radical generation and endotoxemia and precedes pathological liver injury in experimental alcoholic liver disease. Cytokine 2001; 16: 36-39
4. Aleynik SI, Leo MA, Aleynik MK et al. Increased circulating products of lipid peroxidation in patients with alcoholic liver disease. Alcohol Clin Exp Res 1998; 22: 192-196
5. Stickel F, Schuppan D, Hahn EG et al. Cocarcinogenic effects of alcohol in hepatocarcinogenesis. Gut 2002; 51: 132-139
6. Poynard T, Bedossa P, Opolon P. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349: 825-832
7. Salaspuro M. Early Diagnosis and Control of Alcohol Abuse. In: Arroyo V, Bosch J, Rodes J (Hrsg). Treatments in Hepatology. Barcelona: Masson SA 1995; 265-270
8. Borowsky SA, Strome L, Lott E. Continued heavy drinking and survival in alcoholic cirrhosis. Gastroenterology 1981; 80: 1405-1411
9. Teli MR, Day CP, Burt AD et al. Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver. Lancet 1995; 346: 987-980
10. Schenker S. Alcoholic liver disease. Evaluation of natural history and prognostic factors. Hepatology 1984; 4: 36S-43S
11. McCormick PA, Morgan MY, Phillips A et al. The effects of alcohol use on rebleeding and mortality in patients with alcoholic cirrhosis following variceal hemorrhage. J Hepatol 1992; 14: 99-103
12. Pares A, Caballeria J, Bruguera M. Histological course of alcoholic hepatitis: influence of abstinence, sex, and extent of hepatic damage. J Hepatol 1986; 2: 33-42
13. Inoue H, Stickel F, Seitz HK. Individuelles Risikoprofil bei chronischem Alkoholkonsum. Aktuel Ernaehr Med 2001; 26: 39-46
14. Pessione F, Degos F, Marcellin P et al. Effect of alcohol consumption on serum hepatitis C virus RNA and histological lesions in chronic hepatitis C. Hepatology 1998; 27: 1717-1722
15. Degos F. Hepatitis C and alcohol. J Hepatol 1999; 31 (Suppl 1): 113-118
16. McCullough AJ, O'Connor JFB. Alcoholic liver disease: proposed recommendations for the American College of Gastroenterology. Am J Gastroenterol 1998; 93: 2022-2036
17. Myrick H, Brady KT, Malcolm R. New developments in the pharmacotherapy of alcohol dependence. Am J Addict 2001; 10: 3-15
18. Suter PM. Alkohol und Ernährung. In: Seitz HK, Lieber CS, Simanowski UA (Hrsg). Alkohol, Alkoholismus und alkoholbedingte Organschäden 2002; 325-374
19. Caregoro L, Alberino F, Amodio P et al. Malnutrition in alcoholic and virus-related cirrhosis. Am J Clin Nutr 1996; 63: 602-609
20. McCullough AJ, Bugianesi E. Protein-calorie malnutrition and the etiology of cirrhosis. Am J Gastro 1997; 92: 734-738
21. Müller MJ, Lautz HU, Plogmann B et al. Energy expenditure and substrate oxidation in patients with cirrhosis: the impact of cause, clinical staging and nutritional state. Hepatology 1992; 12: 782-794
22. Bianchi G, Marchesini G, Zoli M et al. Prognostic significance of diabetes in patients with cirrhosis. Hepatology 1994; 20: 119-125
23. Mezey E. Effect of ethanol on intestinal morphology, metabolism, and function. In: Seitz HK, Kommerell B (Hrsg). Alcohol related diseases in gastroenterology. New York: Springer 1985; 342-360
24. Leo MA, Lieber CS. Alcohol, vitamin A, and beta-carotene: adverse interactions, including hepatotoxicity and carcinogenicity. Am J Clin Nutr 1999; 69: 1071-1085
25. Cabre E, Gonzales-Huiz F, Abad-LaCruz A et al. Effect of total enteral nutrition on the short-term outcome of several malnourished cirrhotics. Gastroenterology 1990; 98: 715-720
26. Kearn PJ, Young H, Garcia G et al. Accelerated improvement of alcoholic liver disease with enteral nutrition. Gastroenterology 1992; 102: 200-205
27. Marchesini G, Dioguardo FS, Bianchi GP et al. Long term oral branched-chain amino acid treatment in chronic hepatic encephalopahty. J Hepatol 1990; 11: 92-101
28. Hirsch S, Bunout D, DeLamaza P et al. Controlled trial of nutritional supplementation in outpatients with symptomatic alcoholic cirrhosis. J Parent Ent Nutr 1993; 17: 119-124
29. Nielsen K, Kondrup J, Martinsen L et al. Long term oral refeeding of patients with cirrhosis of the liver. Br J Nutr 1995; 74: 557-567
30. McCullough AJ, Tavill AS. Disordered protein and energy metabolism in liver disease. Semin Liv Dis 1991; 11: 265-277
31. Swart GR, Zillikens MC, VanVuure JK et al. Effect of late evening meal on nitrogen balance in patients with cirrhosis of the liver. Br Med J 1989; 299: 1202-1203
32. Zillikens MC, Vandenberg JWO, Wahimena JLD et al. Nocturnal oral glucose supplementation. J Hepatol 1993; 17: 377-383
33. Van de Venne WPHG, Westerterp KR, VanHoek A. Habitual patterns of food intake in patients with liver disease. Clin Nutr 1993; 12: 293-297
34. Müller MJ. Ernärung bei Leberzirrhose. Internist 1998; 39: 247-253
35. Plauth M, Weimann A, Holm E et al. Leitlinien der GASL zur Ernährung bei Lebererkrankungen und Lebertransplantation. Z Gastroenterol 1999; 37: 301-312
36. Selberg O, Böttcher J, Tusch G et al. Identification of high- and low-risk patients before liver transplantation: a prospective cohort study of nutritional and metabolic parameters in 150 patients. Hepatology 1997; 25: 652-657
37. Rojkind M, Uribe M, Kershenobich D. Colchicine and the treatment of liver cirrhosis. Lancet 1973; 1: 38-39
38. Trinchet JC, Beaugrand M, Callard P et al. Treatment of alcoholic hepatitis with colchicine. Results of a randomized double blind trial. Gastroenterol Clin Biol 1989; 13: 551-555
39. Akriviadis EA, Steindel H, Pinto PC et al. Failure of colchicine to improve short-term survival in patients with alcoholic hepatitis. Gastroenterology 1990; 99: 811-818
40. Colman JC, Cromie SL, Cox JM et al. The natural history of alcoholic cirrhosis: effect of colchicine (Abstr.). Hepatology 1998; 28: A510
41. Cortez-Pinto H, Serejo F, Camilo ME et al. Colchicine in alcoholic cirrhosis - preliminary results of a double-blind randomized trial. Gut 1994; 35 (suppl 4): A20
42. Sainz S, Guarner C, Villanueva C et al. Colchicine treatment in alcoholic liver disease. A controlled and randomized study. J. Heptol 1992; 16(suppl 1): A64
43. Rambaldi A, Gluud C. Colchicine for alcoholic and non-alcoholic liver fibrosis or cirrhosis. Liver 2001; 21: 129-136
44. Wellington K, Jarvis B. Silymarin: a review of its clinical properties in the management of hepatic disorders. Bio Drugs 2001; 15: 465-489
45. Salmi HA, Sarna S. Effect of silymarin on chemical, functional and morphological alterations of the liver. A double blind controlled study. Scand J Gastroenterol 1982; 17: 517-521
46. Ferenci P, Dragosic B, Dittrich H et al. Randomized controlled clinical trial of silymarin treatment in patients with cirrhosis of the liver. J Hepatol 1989; 9: 105-113
47. Pares A, Planas R, Torres M et al. Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial. J Hepatol 1998; 28: 615-621
48. Boigk G, Stroedter L, Herbst H et al. Silymarin retards collagen accumulation in early and advanced biliary fibrosis secondary to complete bile duct obliteration in rats. Hepatology 1997; 26: 643-649
49. Morgan M. Alcoholic Liver Disease. Management. In: Bircher J, Benhamou JP, McIntyre N et al (Hrsg). Oxford Textbook of Clinical Hepatology. Oxford: University Press 1999; 1175-1235
50. Imperiale T, McCullough AJ. Do corticosteroids reduce mortality from alcoholic hepatitis? A meta-analysis of the randomized trials. Ann Intern Med 1990; 133: 299-307
51. Reynolds TB, Benhamou JP, Blake J et al. Treatment of acute alcoholic hepatitis. Gastroenterol Int 1989; 2: 208-216
52. Christensen E, Gluud C. Glucocorticosteroids are ineffective in alcoholic hepatitis: a meta-analysis adjusting for confounding variables. Gut 1995; 37: 113-118
53. Cabre E, Rodriguez-Iglesias P, Caballeria J et al. Short-term and long-term outcome of severe alcohol-induced hepatitis treated with steroids or enteral nutrition: a multicenter randomized trial. Hepatology 2000; 32: 36-42
54. Mendenhall CL, Roselle GA, Gartside P et al. Relationship of protein calorie malnutrition to alcoholic liver disease: a reexamination of data from two Veterans Administration Cooperative Studies. Alcohol Clin Exp Res 1995; 19: 635-641
55. Testosterone treatment of men with alcoholic cirrhosis: a double-blind study. The Copenhagen Study Group for Liver Diseases. Hepatology 1986; 6: 807-813
56. Lieber CS. Microsomal ethanol-oxidizing system (MEOS): the first 30 years (1968-1998) - a review. Alcohol Clin Exp Res 1999; 23: 991-1007
57. Larrey D. Drug-induced liver diseases. J Hepatol 2000; 32 (suppl 1): 77-88
58. Morimoto M, Hagbjork AL, Wan YJY et al. Modulation of experimental alcohol-induced liver disease by cytochrome P450 2E1 inhibitors. Hepatology 1995; 21: 1610-1617
59. Kim ND, Kwak MK, Kim SG. Inhibition of cytochrome P450 2E1 expression by 2-(allythio)pyrazine, apotential chemoprotective agent: hepatoprotective effects. Biochem Pharmacol 1997; 53: 261-269
60. Gebhardt AC, Lucas D, Menez JF et al. Chlormethiazole inhibition of cytochrome P450 2E1 as assessed by chlorzoxazone hydroxylation in humans. Hepatology 1997; 26: 957-961
61. Avila MA, Berasain C, Torres L et al. Reduced mRNA abundance of the main enzymes involved in methionine metabolim in human liver cirrhosis and hepatocellular carcinoma J Hepatol 2000; 33: 907-914
62. Frezza M, Surrenti C, Manzillo G et al. Oral S-adenosylmethionine in the symptomatic treatment of intrahepatic cholestasis: a double-blind, placebo controlled study. Gastroenterology 1990; 99: 211-215
63. Lieber CS, Casini A, DeCarli L et al. S-adenosyl-L-methionine attenuates alcohol-induced liver injury in the baboon. Hepatology 1990; 11: 165-172
64. Trimble KC, Molloy AM, Scott JM et al. The effect of ethanol on one-carbon metabolism: increased methionine catabolism and methyl-group wastage. Hepatology 1993; 18: 984-989
65. Stickel F, Choi SW, Kim YI et al. Effect of chronic alcohol consumption on total plasma homocysteine levels in rats. Alcohol Clin Exp Res 2000; 24: 259-264
66. Vendemiale G, Altomare E, Trizio T et al. Effect of oral S-adenosyl-L-methionine on hepatic glutathione in patients with liver disease. Scand J Gastroenterol 1989; 24: 407-415
67. Loguerico C, Nardi G, Argenzio F et al. Effect of S-adenosyl-L-methionine administration on red blood cell cysteine and glutathione levels in alcoholic patients with and without liver disease. Alcohol Alcohol 1994; 29: 597-604
68. Mato JM, Camara J, de Fernandez Paz J et al. S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicentre clinical trial. J Hepatol 1999; 30: 1081-1089
69. Lieber CS. Alcoholic liver disease: new insights in pathogenesis lead to new treatments. J Hepatol 2000; 32 (suppl 2): 113-128
70. Panos MZ, Polson R, Johnson R et al. Polyunsaturated phosphatidylcholine for acute alcoholic hepatitis: a double-blind, randomized, placebocontrolled trial. Europ J Gastroenterol Hepatol 1990; 2: 351-355
71. Schuller-Perez A, Gonzales San Martin F. Plazebo-controlled study with polyunsaturated phosphatidylcholine in alcoholic steatosis of the liver. Med Welt 1985; 36: 517-521
72. Knuschel F. double-blind study in patients with alcoholic steatosis of the liver. Med Welt 1985; 36: 517-521
73. Lieber CS, Weiss DG, Groszmann R et al. Effect of moderation of ethanol consumption combined with PPC administration on liver injury in alcoholics: prospective, randomized, placebo-controlled, multicenter VA trail (CSP 391). Hepatology 2002; 36 (Abstract): 381A
74. Worrier TM, Lieber CS. Perivenular fibrosis as precursor lesion of cirrhosis. J Am Med Assoc 1985; 254: 627-630
75. Paronetto F. Alkohol und Immunsystem. In: Seitz HK, Lieber CS, Simanowski UA (Hrsg). Handbuch Alkohol Alkoholismus Alkoholbedingte Organerkrankungen. Heidelberg, Leipzig: Joahnn Ambrosius Barth 1994; 381-406
76. Tilg H, Diehl AM. Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med 2000; 343: 1467-1476
77. Iimuro Y, Gallucci RM, Luster MI et al. Antibodies to tumor necrosis factor alfa attenuate hepatic necrosis and inflammation caused by chronic exposure to ethanol in the rat. Hepatology 1997; 26: 1530-1537
78. Tilg H, Jalan R, Kaser A et al. Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis. Hepatology (im Druck)
79. Ward A, Clissold SP. Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs 1987; 34: 50-97
80. Akriviadis E, Botla R, Briggs W et al. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000; 119: 1637-1648
81. Caballeria J, Pares A, Bru C et al. Metadoxin accelerates fatty liver recovery in alcoholic patients: results of a randomized double-blind, placebocontrolled trial. J Hepatol 1998; 28: 54-60
82. Schuppan D, Jia JD, Brinkhaus B et al. Herbal products for liver disease: a therapeutic challenge for the new millenium. Hepatology 1999; 30: 1099-1104
83. Fleig WW, Morgan MY, Hblzer MA and a European multicenter study group. The ayurvedic drug LIV.52 in patients with alcoholic cirrhosis. Results of a prospective, randomized, double-blind, placebo-controlled clinical trial (Abstr). J Hepatol 1997; 26 (suppl1): 127A
84. Neuberger J, Schulz KH, Day C et al. Transplantation for alcoholic liver disease. J Hepatol 2002; 36: 130-137
85. Wiesner RH, Lombardero M, Lake JR. Liver transplantation for end-stage alcoholic liver disease: An assessment of outcomes. Transplant Surg 1997; 3: 245-250
86. Neuberger J. Transplantation for alcoholic liver disease: a perspective from Europe. Liver Transpl Surg 1998; 4 (suppl 1): S51-57
87. Berlakovich GA, Langer F, Freundorfer E et al. General compliance after liver transplantation for alcoholic cirrhosis. Transpl Int 2000; 13: 129-135
88. Anand AC, Ferraz-Neto BH, Nightingale P et al. Liver transplantation for alcoholic liver disease: evaluation of a selection protocol. Hepatology 1997; 25: 1478-1484
89. Foster P, Fabrega F, Karademir S et al. Rediction of abstinence from ethanol in alcoholic recipients following liver transplantation. Hepatology 1997; 25: 1469-1477
90. DiMartini A, Jain A, Irish W et al. Outcome of liver transplantation in critically ill patients with alcoholic cirrhosis. Transplantation 1998; 66: 298-302
91. Pageaux PG, Michel J, Coste V et al. Alcoholic cirrhosis is a good indication for liver transplantation even for cases of recidivism. Gut 1999; 45: 421-426
92. Osorio RW, Ascher NL, Avery M et al. Predicting recidivism after orthotopic liver transplantation for alcoholic liver disease. Hepatology 1994; 20: 105-110
93. Keefe EB. Comorbidities of alcoholic liver disease that affect outcome of orthotopic liver transplantation. Liver Transplant Surg 1997; 3: 251-257